share_log

GlaxoSmithKline | 6-K: Viiv Healthcare Announces Interim Data at Croi Indicating Superior Efficacy of Long-Acting Injectable Hiv Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living with Hiv Who Have Adheren

GlaxoSmithKline | 6-K: Viiv Healthcare Announces Interim Data at Croi Indicating Superior Efficacy of Long-Acting Injectable Hiv Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living with Hiv Who Have Adheren

葛蘭素史克 | 6-K：Viiv Healthcare在Croi宣佈中期數據表明，對於有依從性挑戰的HIV感染者，長效注射 HIV治療Cabenuva（Cabotegravir + Rilpivirine）療效優於每日口服治療
SEC announcement ·  03/07 00:13

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。